Heptares Attracts $21m for Clinical Development

Drug discovery and development company Heptares Therapeutics has raised over $21 million in a Series B financing. The round was co-led by the Stanley Family Foundation and current investor Clarus Ventures with Takeda Ventures also participating.

ArmaGen Technologies Raises $17m Series A

ArmaGen Technologies has closed a $17 million Series A financing to support the development of brain-penetrating recombinant protein therapeutics. The lead investor is Boehringer Ingelheim Venture Fund, joined by Shire plc, Takeda Ventures, Inc., and Mitsui & Co. Global Investment, Inc.

Takeda to Acquire Envoy

Takeda America Holdings is to acquire Envoy. Takeda America Holdings will acquire 100 percent of the equity in Envoy for total consideration of up to $140 million, which includes an up-front payment and progress-dependent, preclinical milestone payments. Envoy is a privately-held drug discovery company focused on finding new drugs with superior efficacy and fewer side effects than existing treatments. Takeda’s corporate venture arm, Takeda Ventures, participated in Envoy’s series A financing in October 2009.

Juventas Closes Series B

Cleveland, OH- based Juventas Therapeutics, a clinical-stage regenerative medicine company, has closed a $22.2 million Series B financing that was co-led by Triathlon Medical Venture Partners and New Science Ventures. All previous venture firms, including Fletcher Spaght Ventures, Reservoir Venture Partners and Early Stage Partners participated in the round. Also joining the syndicate are new […]

PE HUB Community

Join the 12522 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget